Clinical Trial

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to determine the feasibility, safety, tolerability and maximum tolerated dose of Venetoclax in combination with Blinatumomab and to evaluate the response in patients treated with the combination of Venetoclax and Blinatumomab in in patients with hematological relapse or molecular relapse.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-06; most recent amendment 2025-07-22.
Status change: Recruiting → Active, Not Recruiting 2025-07-22
Trial Details
NCT Number NCT05182385
Lead Sponsor Goethe University
Collaborators: University Hospital Schleswig-Holstein
Conditions ALL, Recurrent, Adult
Enrollment 30 participants
Start Date 2021-12-15
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-25